Treats major depressive disorder (MDD). ANDA 76711, held by Impax Labs. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 76711 (Bupropion Hydrochloride), held by Impax Labs, was first approved by FDA on Dec 3, 2004, with 20 approved supplements and 0 published complete response letters.
Bupropion hydrochloride extended-release tablets (SR) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD. The efficacy of bupropion hydrochloride extended-release tablets (SR) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bupropion Hydrochloride200MG · tablet, extended release;oral | Bupropion Hydrochloride | Discontinued |
| Jan 29, 2025 | Supplement 43Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 41Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 42Labeling · Standard review | Approved | None posted |
| Jan 4, 2021 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jan 4, 2021 | Supplement 31Labeling · Standard review | Approved | None posted |
| Jan 4, 2021 | Supplement 32Labeling · Standard review | Approved | None posted |
| Jan 4, 2021 | Supplement 39Labeling · Standard review | Approved | None posted |
| Jan 4, 2021 | Supplement 40Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 23Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 24Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 27Labeling · Standard review | Approved | None posted |
| Feb 21, 2012 | Supplement 13Labeling | Approved | None posted |
| Feb 21, 2012 | Supplement 14Labeling | Approved | None posted |
| Aug 18, 2010 | Supplement 12Labeling | Approved | None posted |
| Jul 8, 2010 | Supplement 11REMS | Approved | None posted |
| Jan 27, 2010 | Supplement 9Labeling | Approved | None posted |
| Jan 16, 2008 | Supplement 7Labeling | Approved | None posted |
| Oct 5, 2006 | Supplement 5Labeling | Approved | None posted |
| Feb 14, 2006 | Supplement 3Labeling | Approved | None posted |
| Dec 3, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters